Bronchial asthma with normal forced expiratory volume in 1 second (FEV1) compared with low FEV1
Cough variant asthma (CVA) is characterized by cough as a sole symptom and normal pulmonary function. However, it is unclear whether CVA really common among asthmatic patients with normal forced expiratory volume in 1 second (FEV1). The aim of this study was to evaluate the incidence of cough alone...
Saved in:
Published in | Journal of thoracic disease Vol. 16; no. 9; pp. 5580 - 5590 |
---|---|
Main Authors | , |
Format | Journal Article |
Language | English |
Published |
China
AME Publishing Company
30.09.2024
|
Subjects | |
Online Access | Get full text |
Cover
Loading…
Abstract | Cough variant asthma (CVA) is characterized by cough as a sole symptom and normal pulmonary function. However, it is unclear whether CVA really common among asthmatic patients with normal forced expiratory volume in 1 second (FEV1). The aim of this study was to evaluate the incidence of cough alone symptom among the subjects with normal FEV1 and to evaluate their differences from ordinary asthmatic subjects.
We defined normal FEV1 as ≥90% predicted based on the article of Kotti GH. Of the patients with normal FEV1, we chose subjects without wheeze, and the duration of cough was not to ask, since the symptoms often occurred with acute exacerbation and timing of visiting a doctor depended on each patient's perception. Test for airway hyperresponsiveness was not performed in this study. Visual analogue scale (VAS) scores for cough and dyspnea, FEV1, and fractional exhaled nitric oxide (FeNO) responsiveness to inhaled corticosteroid (ICS)/long-acting beta2 agonist (LABA) treatment were compared in patients with normal FEV1 and with low FEV1 <90%. Correlations of changes in symptoms with changes of FEV1, FeNO, peripheral eosinophil count, and serum immunoglobulin E (IgE) at single time point were also examined in each group and in overall patients.
The participants were 329 physician-diagnosed treatment-naive patients with asthma who were divided into 187 in normal FEV1 and 142 in low FEV1 groups. Cough without dyspnea was present in 16 patients (8.6%) in the normal FEV1 group, suggesting candidates for CVA in this analysis were quite few. Improvement in symptoms after treatment was similar between both groups. But VAS scores of dyspnea were still higher in the low FEV1 group. The degree of improvement in FEV1 after ICS/LABA treatment was less in the normal FEV1 group than in the low FEV1 group, but was still evident. Peripheral eosinophil count, serum IgE, and FeNO values before treatment were lower in the normal FEV1 group. In overall patients, improvements of symptoms after treatment were significantly correlated with FEV1 changes. Improvement of dyspnea was also significantly related to peripheral eosinophil count and change of FeNO, whereas improvement of cough was not related to these T helper 2 (Th2) response markers.
Candidates for CVA among the patients with asthma with predicted FEV1 ≥90% were few. Participants with normal FEV1 respond well to ICS/LABA treatment for improvement of symptom. The change of FEV1 after treatment, and the pre-treatment blood eosinophil count, serum IgE, and FeNO were lower in normal FEV1 cases than in low FEV1 cases. These observations suggest asthmatic patients with normal FEV1, including candidates for CVA having just common mild asthma. In overall participants, symptoms of cough and dyspnea were similar, but were not identical in relation to the Th2 background. |
---|---|
AbstractList | Cough variant asthma (CVA) is characterized by cough as a sole symptom and normal pulmonary function. However, it is unclear whether CVA really common among asthmatic patients with normal forced expiratory volume in 1 second (FEV1). The aim of this study was to evaluate the incidence of cough alone symptom among the subjects with normal FEV1 and to evaluate their differences from ordinary asthmatic subjects.
We defined normal FEV1 as ≥90% predicted based on the article of Kotti GH. Of the patients with normal FEV1, we chose subjects without wheeze, and the duration of cough was not to ask, since the symptoms often occurred with acute exacerbation and timing of visiting a doctor depended on each patient's perception. Test for airway hyperresponsiveness was not performed in this study. Visual analogue scale (VAS) scores for cough and dyspnea, FEV1, and fractional exhaled nitric oxide (FeNO) responsiveness to inhaled corticosteroid (ICS)/long-acting beta2 agonist (LABA) treatment were compared in patients with normal FEV1 and with low FEV1 <90%. Correlations of changes in symptoms with changes of FEV1, FeNO, peripheral eosinophil count, and serum immunoglobulin E (IgE) at single time point were also examined in each group and in overall patients.
The participants were 329 physician-diagnosed treatment-naive patients with asthma who were divided into 187 in normal FEV1 and 142 in low FEV1 groups. Cough without dyspnea was present in 16 patients (8.6%) in the normal FEV1 group, suggesting candidates for CVA in this analysis were quite few. Improvement in symptoms after treatment was similar between both groups. But VAS scores of dyspnea were still higher in the low FEV1 group. The degree of improvement in FEV1 after ICS/LABA treatment was less in the normal FEV1 group than in the low FEV1 group, but was still evident. Peripheral eosinophil count, serum IgE, and FeNO values before treatment were lower in the normal FEV1 group. In overall patients, improvements of symptoms after treatment were significantly correlated with FEV1 changes. Improvement of dyspnea was also significantly related to peripheral eosinophil count and change of FeNO, whereas improvement of cough was not related to these T helper 2 (Th2) response markers.
Candidates for CVA among the patients with asthma with predicted FEV1 ≥90% were few. Participants with normal FEV1 respond well to ICS/LABA treatment for improvement of symptom. The change of FEV1 after treatment, and the pre-treatment blood eosinophil count, serum IgE, and FeNO were lower in normal FEV1 cases than in low FEV1 cases. These observations suggest asthmatic patients with normal FEV1, including candidates for CVA having just common mild asthma. In overall participants, symptoms of cough and dyspnea were similar, but were not identical in relation to the Th2 background. Cough variant asthma (CVA) is characterized by cough as a sole symptom and normal pulmonary function. However, it is unclear whether CVA really common among asthmatic patients with normal forced expiratory volume in 1 second (FEV1). The aim of this study was to evaluate the incidence of cough alone symptom among the subjects with normal FEV1 and to evaluate their differences from ordinary asthmatic subjects.BackgroundCough variant asthma (CVA) is characterized by cough as a sole symptom and normal pulmonary function. However, it is unclear whether CVA really common among asthmatic patients with normal forced expiratory volume in 1 second (FEV1). The aim of this study was to evaluate the incidence of cough alone symptom among the subjects with normal FEV1 and to evaluate their differences from ordinary asthmatic subjects.We defined normal FEV1 as ≥90% predicted based on the article of Kotti GH. Of the patients with normal FEV1, we chose subjects without wheeze, and the duration of cough was not to ask, since the symptoms often occurred with acute exacerbation and timing of visiting a doctor depended on each patient's perception. Test for airway hyperresponsiveness was not performed in this study. Visual analogue scale (VAS) scores for cough and dyspnea, FEV1, and fractional exhaled nitric oxide (FeNO) responsiveness to inhaled corticosteroid (ICS)/long-acting beta2 agonist (LABA) treatment were compared in patients with normal FEV1 and with low FEV1 <90%. Correlations of changes in symptoms with changes of FEV1, FeNO, peripheral eosinophil count, and serum immunoglobulin E (IgE) at single time point were also examined in each group and in overall patients.MethodsWe defined normal FEV1 as ≥90% predicted based on the article of Kotti GH. Of the patients with normal FEV1, we chose subjects without wheeze, and the duration of cough was not to ask, since the symptoms often occurred with acute exacerbation and timing of visiting a doctor depended on each patient's perception. Test for airway hyperresponsiveness was not performed in this study. Visual analogue scale (VAS) scores for cough and dyspnea, FEV1, and fractional exhaled nitric oxide (FeNO) responsiveness to inhaled corticosteroid (ICS)/long-acting beta2 agonist (LABA) treatment were compared in patients with normal FEV1 and with low FEV1 <90%. Correlations of changes in symptoms with changes of FEV1, FeNO, peripheral eosinophil count, and serum immunoglobulin E (IgE) at single time point were also examined in each group and in overall patients.The participants were 329 physician-diagnosed treatment-naive patients with asthma who were divided into 187 in normal FEV1 and 142 in low FEV1 groups. Cough without dyspnea was present in 16 patients (8.6%) in the normal FEV1 group, suggesting candidates for CVA in this analysis were quite few. Improvement in symptoms after treatment was similar between both groups. But VAS scores of dyspnea were still higher in the low FEV1 group. The degree of improvement in FEV1 after ICS/LABA treatment was less in the normal FEV1 group than in the low FEV1 group, but was still evident. Peripheral eosinophil count, serum IgE, and FeNO values before treatment were lower in the normal FEV1 group. In overall patients, improvements of symptoms after treatment were significantly correlated with FEV1 changes. Improvement of dyspnea was also significantly related to peripheral eosinophil count and change of FeNO, whereas improvement of cough was not related to these T helper 2 (Th2) response markers.ResultsThe participants were 329 physician-diagnosed treatment-naive patients with asthma who were divided into 187 in normal FEV1 and 142 in low FEV1 groups. Cough without dyspnea was present in 16 patients (8.6%) in the normal FEV1 group, suggesting candidates for CVA in this analysis were quite few. Improvement in symptoms after treatment was similar between both groups. But VAS scores of dyspnea were still higher in the low FEV1 group. The degree of improvement in FEV1 after ICS/LABA treatment was less in the normal FEV1 group than in the low FEV1 group, but was still evident. Peripheral eosinophil count, serum IgE, and FeNO values before treatment were lower in the normal FEV1 group. In overall patients, improvements of symptoms after treatment were significantly correlated with FEV1 changes. Improvement of dyspnea was also significantly related to peripheral eosinophil count and change of FeNO, whereas improvement of cough was not related to these T helper 2 (Th2) response markers.Candidates for CVA among the patients with asthma with predicted FEV1 ≥90% were few. Participants with normal FEV1 respond well to ICS/LABA treatment for improvement of symptom. The change of FEV1 after treatment, and the pre-treatment blood eosinophil count, serum IgE, and FeNO were lower in normal FEV1 cases than in low FEV1 cases. These observations suggest asthmatic patients with normal FEV1, including candidates for CVA having just common mild asthma. In overall participants, symptoms of cough and dyspnea were similar, but were not identical in relation to the Th2 background.ConclusionsCandidates for CVA among the patients with asthma with predicted FEV1 ≥90% were few. Participants with normal FEV1 respond well to ICS/LABA treatment for improvement of symptom. The change of FEV1 after treatment, and the pre-treatment blood eosinophil count, serum IgE, and FeNO were lower in normal FEV1 cases than in low FEV1 cases. These observations suggest asthmatic patients with normal FEV1, including candidates for CVA having just common mild asthma. In overall participants, symptoms of cough and dyspnea were similar, but were not identical in relation to the Th2 background. |
Author | Ohwada, Akihiko Kitaoka, Hiroko |
Author_xml | – sequence: 1 givenname: Akihiko surname: Ohwada fullname: Ohwada, Akihiko – sequence: 2 givenname: Hiroko surname: Kitaoka fullname: Kitaoka, Hiroko |
BackLink | https://www.ncbi.nlm.nih.gov/pubmed/39444879$$D View this record in MEDLINE/PubMed |
BookMark | eNpVkU1PwzAMhiM0xOdO3FGOQ6iQ7zYnBNMGSJO4ANcoTVNW1CYj6YD9e8I2EPhiy378WvJ7CAbOOwvACUYXBCOaX772VUZYVohiBxwQlOeZEIQN1jXJMKNyHwxjfEUpBCIkz_fAPpWMsSKXB0DdBO_MvNEt1LGfdxp-NP0cOh-61Kp9MLaC9nPRBN37sILvvl12FjYOYhit8a6Co-nkGZ9B47uFDoleC7T-A373j8Furdtoh9t8BJ6mk8fxXTZ7uL0fX88yQxnqM0ElLUpRI0p1YWtNCTOcmaoUJa9zLglFuqTGIMmEtFqyAouizBGvGbIsbR2Bq43uYll2tjLW9UG3ahGaToeV8rpR_yeumasX_64wZpJxLpLCaKsQ_NvSxl51TTS2bbWzfhkVxQQhLjkvEnr699jvlZ-3JuB8A5jgYwy2_kUwUmvfVPJNEaaSb_QL6-2Jvw |
ContentType | Journal Article |
Copyright | 2024 AME Publishing Company. All rights reserved. 2024 AME Publishing Company. All rights reserved. 2024 AME Publishing Company. |
Copyright_xml | – notice: 2024 AME Publishing Company. All rights reserved. – notice: 2024 AME Publishing Company. All rights reserved. 2024 AME Publishing Company. |
DBID | AAYXX CITATION NPM 7X8 5PM |
DOI | 10.21037/jtd-24-868 |
DatabaseName | CrossRef PubMed MEDLINE - Academic PubMed Central (Full Participant titles) |
DatabaseTitle | CrossRef PubMed MEDLINE - Academic |
DatabaseTitleList | PubMed MEDLINE - Academic |
Database_xml | – sequence: 1 dbid: NPM name: PubMed url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database |
DeliveryMethod | fulltext_linktorsrc |
Discipline | Medicine |
EISSN | 2077-6624 |
EndPage | 5590 |
ExternalDocumentID | PMC11494556 39444879 10_21037_jtd_24_868 |
Genre | Journal Article |
GroupedDBID | 53G AAKDD AAWTL AAYXX ACGFO ADBBV AENEX AIAGR ALMA_UNASSIGNED_HOLDINGS BAWUL BMSDO CITATION DIK GX1 HYE OK1 RPM NPM 7X8 5PM |
ID | FETCH-LOGICAL-c340t-63938b6f033a8efa324c54cdb6b5f759230ab3cc09469ea948168b705f40e4033 |
ISSN | 2072-1439 |
IngestDate | Thu Aug 21 18:31:01 EDT 2025 Fri Jul 11 09:42:34 EDT 2025 Thu Apr 03 07:05:56 EDT 2025 Tue Jul 01 02:13:50 EDT 2025 |
IsDoiOpenAccess | true |
IsOpenAccess | true |
IsPeerReviewed | false |
IsScholarly | true |
Issue | 9 |
Keywords | Cough variant asthma (CVA) mild asthma normal forced expiratory volume in 1 second (normal FEV1) |
Language | English |
License | 2024 AME Publishing Company. All rights reserved. Open Access Statement: This is an Open Access article distributed in accordance with the Creative Commons Attribution-NonCommercial-NoDerivs 4.0 International License (CC BY-NC-ND 4.0), which permits the non-commercial replication and distribution of the article with the strict proviso that no changes or edits are made and the original work is properly cited (including links to both the formal publication through the relevant DOI and the license). See: https://creativecommons.org/licenses/by-nc-nd/4.0. |
LinkModel | OpenURL |
MergedId | FETCHMERGED-LOGICAL-c340t-63938b6f033a8efa324c54cdb6b5f759230ab3cc09469ea948168b705f40e4033 |
Notes | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 23 Contributions: (I) Conception and design: A Ohwada; (II) Administrative support: A Ohwada; (III) Provision of study materials or patients: A Ohwada; (IV) Collection and assembly of data: A Ohwada; (V) Data analysis and interpretation: A Ohwada; (VI) Manuscript writing: Both authors; (VII) Final approval of manuscript: Both authors. |
OpenAccessLink | https://pubmed.ncbi.nlm.nih.gov/PMC11494556 |
PMID | 39444879 |
PQID | 3120059558 |
PQPubID | 23479 |
PageCount | 11 |
ParticipantIDs | pubmedcentral_primary_oai_pubmedcentral_nih_gov_11494556 proquest_miscellaneous_3120059558 pubmed_primary_39444879 crossref_primary_10_21037_jtd_24_868 |
ProviderPackageCode | CITATION AAYXX |
PublicationCentury | 2000 |
PublicationDate | 2024-09-30 |
PublicationDateYYYYMMDD | 2024-09-30 |
PublicationDate_xml | – month: 09 year: 2024 text: 2024-09-30 day: 30 |
PublicationDecade | 2020 |
PublicationPlace | China |
PublicationPlace_xml | – name: China |
PublicationTitle | Journal of thoracic disease |
PublicationTitleAlternate | J Thorac Dis |
PublicationYear | 2024 |
Publisher | AME Publishing Company |
Publisher_xml | – name: AME Publishing Company |
SSID | ssj0000602277 |
Score | 2.3374815 |
Snippet | Cough variant asthma (CVA) is characterized by cough as a sole symptom and normal pulmonary function. However, it is unclear whether CVA really common among... |
SourceID | pubmedcentral proquest pubmed crossref |
SourceType | Open Access Repository Aggregation Database Index Database |
StartPage | 5580 |
SubjectTerms | Original |
Title | Bronchial asthma with normal forced expiratory volume in 1 second (FEV1) compared with low FEV1 |
URI | https://www.ncbi.nlm.nih.gov/pubmed/39444879 https://www.proquest.com/docview/3120059558 https://pubmed.ncbi.nlm.nih.gov/PMC11494556 |
Volume | 16 |
hasFullText | 1 |
inHoldings | 1 |
isFullTextHit | |
isPrint | |
link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV3ri9NAEF_0BPGL-LbngxXug1KiyT7S5KNIS5F7fGml35bNJktzPRO55rjDv96ZbB5NVTj9EsJuOgnzG6Yzs_Mg5CgNRMaMDrwosNYTqeVerMPE45GWScpsEPlYnHxyGs6X4utKrvrpbXV1SZV8ND__WFfyP6jCGuCKVbL_gGxHFBbgHvCFKyAM11thDD50gbnKF2O9rdbftYuqFmiG1mWJeLaf3XRH6U4TYYQjGG_REa4DCLPptwBjA8Ns9Ivyeow7fzFeqzWIjsnN_gHP2fpapy5Uu8nX-absz_grXW7qnXl-WTYbTbiBiTY3otVKzJ8wD4yseKBCwx1RiXf0oZRuTtO-omZNrf95lXrwjsiN1hm2wz49U7Pl8bFaTFeLu-QeAz-A74Rj3F8tdkDEkvjus1wNZk3_U099aHX85krsZ8TumBiLR-Rhw1762QH9mNzJiifk_kmT_fCUqA5v6vCmCBV1eFOHN-3xpo5tNC9oQB3e9D1i-oG2WDsCgDXF9WdkOZsuvsy9ZkCGZ7jwKw-sSx4lofU511FmNRjHRgqTJmEi7USC7e7rhBsDLnwYZxob84RRMvGlFX4m4FfPyUFRFtlLQkXEU8G1Af3OhQUbl2uGnZNsiAMFmB6Ro5aB6ofrg6LAf6z5rIDPigkFfB6Rdy1zFegpPHzSRVZebRUPMH4Zg0CMyAvH7I4QFmeD4xyPSDSAoXsAe6APd4p8XfdCB3c-FlKGh7d48SvyoJfo1-SgurzK3oBJWSVva7H6BRoAeBw |
linkProvider | National Library of Medicine |
openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Bronchial+asthma+with+normal+forced+expiratory+volume+in+1+second+%28FEV1%29+compared+with+low+FEV1&rft.jtitle=Journal+of+thoracic+disease&rft.au=Ohwada%2C+Akihiko&rft.au=Kitaoka%2C+Hiroko&rft.date=2024-09-30&rft.issn=2072-1439&rft.volume=16&rft.issue=9&rft.spage=5580&rft_id=info:doi/10.21037%2Fjtd-24-868&rft.externalDBID=NO_FULL_TEXT |
thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=2072-1439&client=summon |
thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=2072-1439&client=summon |
thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=2072-1439&client=summon |